Abstract
Agomelatine is a novel antidepressant drug with melatoninergic (MT1/MT2 receptor agonist) and 5-HT2c receptor antagonist activity. Because of favorable side effect profile, it is associated with good treatment adherence. Agomelatine has demonstrated its antidepressant efficacy in five double-blind placebo controlled short-term studies, an extended to 10 months relapse prevention trial and head-to-head comparative clinical trials (paroxetine, sertraline, fluoxetine, escitalopram, venlafaxine). In the published researches, it is shown that agomelatine is superior to placebo in antidepressant efficacy, comparable to other antidepressants and well tolerated than other antidepressants. The positive effects of agomelatine on anxiety and sleep-wake cycles are remarkable. There were no sexual adverse effects of agomelatine reported in the clinical trials, even it can improve the symptoms of sexual disorder due to major depression. Clinical practice will support the evidence from clinical trials in future.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
